STAR Clinical Trial Controversial Among Some Advocacy Groups

Publication
Article
OncologyONCOLOGY Vol 13 No 7
Volume 13
Issue 7

The NCI brushed aside the concerns of some cancer advocacy groups and decided to begin the Study of Tamoxifen and Raloxifene (STAR),expected to be one of the largest breast cancer prevention trials ever. Raloxifene (Evista) was approved

The NCI brushed aside the concerns of some cancer advocacy groups and decided to begin the Study of Tamoxifen and Raloxifene (STAR),expected to be one of the largest breast cancer prevention trials ever. Raloxifene (Evista) was approved by the FDA in December 1997 to prevent osteoporosis. Tamoxifen (Nolvadex) received FDA approval in October 1998 to reduce the risk of breast cancer in women at high risk for the disease. The STAR trial will compare the impact of the two drugs on women at risk for breast cancer, with particular emphasis on side effects. Women in previous trials of both raloxifene and tamoxifen have shown an increased incidence of deep vein thrombosis and pulmonary embolism, but raloxifene has not produced the endometrial cancer risk that tamoxifen has.

In announcing STAR, Donna Shalala, secretary of the Department of Health and Human Services, said, “Women who are at high risk of developing breast cancer need more and better prevention options, and only through clinical trials such as STAR will we find those options.” But groups such as the National Breast Cancer Coalition have strong reservations. The group said in a statement: “What we do know about tamoxifen as risk reduction is known only for the population of women who actually enrolled in the tamoxifen prevention trial. It is inappropriate to study a different population of healthy women as planned for the STAR trial.”

Recent Videos
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content